List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/971109/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Nordic Countries as a Cohort for Pharmacoepidemiological Research. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 86-94.	1.2	460
2	Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ: British Medical Journal, 2006, 333, 726.	2.4	324
3	Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ, The, 2021, 373, n1114.	3.0	298
4	Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ, The, 2012, 345, e7085-e7085.	3.0	185
5	SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ, The, 2021, 375, e068665.	3.0	179
6	Selective Serotonin Reuptake Inhibitors and the Risk of Stroke. Stroke, 2002, 33, 1465-1473.	1.0	133
7	Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 707-722.	0.7	131
8	Contacts to the health care system prior to suicide: a comprehensive analysis using registers for general and psychiatric hospital admissions, contacts to general practitioners and practising specialists and drug prescriptions. Acta Psychiatrica Scandinavica, 2000, 102, 126-134.	2.2	122
9	Maternal vaginal microflora during pregnancy and the risk of asthma hospitalization and use of antiasthma medication in early childhood. Journal of Allergy and Clinical Immunology, 2002, 110, 72-77.	1.5	109
10	Cancer Risk in Users of Calcium Channel Blockers. Hypertension, 1997, 29, 1091-1094.	1.3	109
11	Exposure to potential drug interactions in primary health care. Scandinavian Journal of Primary Health Care, 2003, 21, 153-158.	0.6	107
12	Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiology and Drug Safety, 2009, 18, 483-491.	0.9	99
13	Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies. Current Drug Safety, 2013, 8, 333-348.	0.3	95
14	Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. European Journal of Clinical Pharmacology, 1997, 52, 183-189.	0.8	93
15	Disulfiram therapy –adverse drug reactions and interactions. Acta Psychiatrica Scandinavica, 1992, 86, 59-66.	2.2	91
16	High persistence of statin use in a Danish population: Compliance study 1993-1998. British Journal of Clinical Pharmacology, 2002, 53, 375-378.	1.1	91
17	Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications. Frontiers in Pharmacology, 2010, 1, 141.	1.6	90
18	Methods for timeâ€varying exposure related problems in pharmacoepidemiology: An overview. Pharmacoepidemiology and Drug Safety, 2018, 27, 148-160.	0.9	89

#	Article	IF	CITATIONS
19	Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs. Stroke, 2003, 34, 379-386.	1.0	86
20	Rising prevalence of diabetes: evidence from a Danish pharmacoepidemiological database Lancet, The, 2003, 362, 537-538.	6.3	81
21	Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?. Pharmaceuticals, 2010, 3, 2470-2494.	1.7	76
22	How Conducting a Clinical Trial Affects Physicians' Guideline Adherence and Drug Preferences. JAMA - Journal of the American Medical Association, 2006, 295, 2759.	3.8	75
23	Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder. Schizophrenia Research, 2011, 133, 36-41.	1.1	72
24	Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. European Journal of Clinical Pharmacology, 2001, 57, 517-521.	0.8	67
25	Exposure to antiepileptic drugs and the risk of hip fracture: A caseâ€control study. Epilepsia, 2008, 49, 2092-2099.	2.6	61
26	The Asian Pharmacoepidemiology Network (AsPEN): promoting multiâ€national collaboration for pharmacoepidemiologic research in Asia. Pharmacoepidemiology and Drug Safety, 2013, 22, 700-704.	0.9	61
27	Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. European Journal of Clinical Pharmacology, 2001, 56, 923-929.	0.8	60
28	Long term use of drugs affecting the reninâ€angiotensin system and the risk of cancer: a populationâ€based caseâ€control study. British Journal of Clinical Pharmacology, 2012, 74, 180-188.	1.1	60
29	Adherence to preventive statin therapy according to socioeconomic position. European Journal of Clinical Pharmacology, 2013, 69, 1553-1563.	0.8	60
30	Diagnostic Potential of miR-126, miR-143, miR-145, and miR-652 in Malignant Pleural Mesothelioma. Journal of Molecular Diagnostics, 2014, 16, 418-430.	1.2	57
31	Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia, 2017, 60, 1691-1703.	2.9	57
32	Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non–Vitamin K Antagonist Oral Anticoagulants. Stroke, 2018, 49, 2122-2128.	1.0	56
33	Use of Opioids in a Danish Population-Based Cohort of Cancer Patients. Journal of Pain and Symptom Management, 2005, 29, 336-343.	0.6	53
34	CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis. Current Drug Safety, 2013, 8, 296-332.	0.3	52
35	Antihypertensive medication and the risk of acute pancreatitis: The European case-control study on drug-induced acute pancreatitis (EDIP). Scandinavian Journal of Gastroenterology, 2006, 41, 1484-1490.	0.6	51
36	Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. British Journal of Clinical Pharmacology, 2000, 49, 463-471.	1.1	49

#	Article	IF	CITATIONS
37	Use of sumatriptan in Denmark in 1994-5: an epidemiological analysisof nationwide prescription data. British Journal of Clinical Pharmacology, 1997, 43, 429-433.	1.1	48
38	Use of a Prescribed Ephedrine/Caffeine Combination and the Risk of Serious Cardiovascular Events: A Registry-based Case-Crossover Study. American Journal of Epidemiology, 2008, 168, 966-973.	1.6	47
39	Diabetes and Breast Cancer Subtypes. PLoS ONE, 2017, 12, e0170084.	1.1	47
40	Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace, 2018, 20, 420-428.	0.7	46
41	Drug-related fatal anaphylactic shock in Denmark 1968–1990. A study based on notifications to the Committee on Adverse Drug Reactions. Journal of Clinical Epidemiology, 1995, 48, 1185-1188.	2.4	45
42	Multi ountry rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiology and Drug Safety, 2013, 22, 915-924.	0.9	45
43	Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A crossâ€national drug utilization study. British Journal of Clinical Pharmacology, 2019, 85, 2524-2539.	1.1	41
44	Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. European Journal of Clinical Pharmacology, 1998, 54, 701-706.	0.8	40
45	Drug prescribing among Danish children: a population-based study. European Journal of Clinical Pharmacology, 2001, 57, 159-165.	0.8	40
46	A randomized trial of laypersons' perception of the benefit of osteoporosis therapy: Number needed to treat versus postponement of hip fracture. Clinical Therapeutics, 2003, 25, 2575-2585.	1.1	40
47	Cardiovascular drugs and the risk of suicide: a nested case-control study. European Journal of Clinical Pharmacology, 2007, 63, 591-596.	0.8	40
48	Patterns of antibiotic use in the community in Denmark. Scandinavian Journal of Infectious Diseases, 2006, 38, 597-603.	1.5	39
49	Impact of pharmaceutical representative visits on GPs' drug preferences. Family Practice, 2009, 26, 204-209.	0.8	39
50	Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. British Journal of Clinical Pharmacology, 2017, 83, 642-652.	1.1	39
51	Detailed postal feedback about prescribing to asthma patients combined with a guideline statement showed no impact: a randomised controlled trial. European Journal of Clinical Pharmacology, 2002, 58, 127-132.	0.8	38
52	Is it Possible to Measure Prescribing Quality using only Prescription Data?. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 314-319.	1.2	38
53	Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a populationâ€based caseâ€control study. British Journal of Clinical Pharmacology, 2013, 75, 1356-1364.	1.1	38
54	Mailed prescriber feedback in addition to a clinical guideline has no impact: a randomised, controlled trial. Scandinavian Journal of Primary Health Care, 2003, 21, 47-51.	0.6	37

MORTEN ANDERSEN

#	Article	IF	CITATIONS
55	Spironolactone use and the risk of upper gastrointestinal bleeding: a populationâ€based case–control study. British Journal of Clinical Pharmacology, 2008, 66, 294-299.	1.1	37
56	Multimorbidity and Blood Pressure Control in 37Â651 Hypertensive Patients From Danish General Practice. Journal of the American Heart Association, 2013, 2, e004531.	1.6	36
57	Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines. Expert Opinion on Drug Safety, 2021, 20, 1451-1453.	1.0	36
58	Statin utilization according to indication and age: A Danish cohort study on changing prescribing and purchasing behaviour. Health Policy, 2012, 108, 216-227.	1.4	35
59	The impact of population ageing on future Danish drug expenditure. Health Policy, 2006, 75, 298-311.	1.4	34
60	Factors influencing GPs' choice between drugs in a therapeutic drug group. A qualitative study. Scandinavian Journal of Primary Health Care, 2007, 25, 208-213.	0.6	33
61	Associations between generic substitution and patients' attitudes, beliefs and experiences. European Journal of Clinical Pharmacology, 2013, 69, 1827-1836.	0.8	33
62	Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-91. Journal of Internal Medicine, 1996, 239, 509-515.	2.7	30
63	Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma. Anticancer Research, 2015, 35, 6223-9.	0.5	30
64	Deviations from evidence-based prescribing of non-steroidal anti-inflammatory drugs in three European regions. European Journal of Clinical Pharmacology, 2000, 56, 269-272.	0.8	29
65	Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase®. Scientific Reports, 2019, 9, 7236.	1.6	29
66	Cancer Risk in Long-term Users of Valproate: A Population-Based Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1714-1719.	1.1	28
67	Problems in collecting comparable national drug use data in Europe: the example of antibacterials. European Journal of Clinical Pharmacology, 2003, 58, 843-849.	0.8	27
68	Hyponatremia in elderly patients treated with desmopressin for nocturia: a review of a case series. European Journal of Clinical Pharmacology, 2005, 61, 281-284.	0.8	26
69	Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model. British Journal of Clinical Pharmacology, 2008, 66, 885-895.	1.1	25
70	General practitioners prefer prescribing indicators based on detailed information on individual patients: a Delphi study. European Journal of Clinical Pharmacology, 2005, 61, 237-241.	0.8	24
71	Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. Pharmacoepidemiology and Drug Safety, 2012, 21, 1027-1035.	0.9	24
72	Does the early adopter of drugs exist? A population-based study of general practitioners? prescribing of new drugs. European Journal of Clinical Pharmacology, 2004, 60, 667-672.	0.8	23

#	Article	IF	CITATIONS
73	Intensive community pharmacy intervention had little impact on triptan consumption: A randomized controlled trial. Scandinavian Journal of Primary Health Care, 2006, 24, 16-21.	0.6	22
74	The Danish Model for Improvement of Diabetes Care in General Practice: Impact of Automated Collection and Feedback of Patient Data. International Journal of Family Medicine, 2012, 2012, 1-5.	1.2	22
75	Initiation and longâ€ŧerm use of benzodiazepines and Zâ€drugs in bipolar disorder. Bipolar Disorders, 2018, 20, 634-646.	1.1	22
76	Adverse Reactions to H2-Receptor Antagonists in Denmark Before and After Transfer of Cimetidine and Ranitidine to Over-the-counter Status. Basic and Clinical Pharmacology and Toxicology, 1991, 69, 253-258.	0.0	21
77	Cancer patients' share in a population's Use of opioids. A linkage study between a prescription database and the danish cancer registry. Journal of Pain and Symptom Management, 2004, 27, 36-43.	0.6	21
78	Frequency of Opioid Use in a Population of Cancer Patients During the Trajectory of the Disease. Clinical Oncology, 2010, 22, 199-207.	0.6	21
79	Why has postal prescriber feedback no substantial impact on general practitioners' prescribing practice? A qualitative study. European Journal of Clinical Pharmacology, 2002, 58, 133-136.	0.8	20
80	General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study. British Journal of Clinical Pharmacology, 2005, 60, 526-533.	1.1	20
81	Generic Switching and Non-Persistence among Medicine Users: A Combined Population-Based Questionnaire and Register Study. PLoS ONE, 2015, 10, e0119688.	1.1	20
82	Introduction to drug utilization research. , 2016, , 1-12.		20
83	Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. British Journal of Clinical Pharmacology, 2021, 87, 988-1000.	1.1	19
84	Do statins protect against upper gastrointestinal bleeding?. British Journal of Clinical Pharmacology, 2009, 67, 460-465.	1.1	18
85	Increased use of inhaled corticosteroids among young Danish adult asthmatics: An observational study. Respiratory Medicine, 2010, 104, 1817-1824.	1.3	18
86	Association between prescribing patterns of anti-asthmatic drugs and clinically uncontrolled asthma: A cross-sectional study. Pulmonary Pharmacology and Therapeutics, 2011, 24, 647-653.	1.1	18
87	Data management and data analysis techniques in pharmacoepidemiological studies using a preâ€planned multiâ€database approach: a systematic literature review. Pharmacoepidemiology and Drug Safety, 2015, 24, 897-905.	0.9	18
88	Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. American Journal of Cardiology, 2020, 125, 1069-1076.	0.7	18
89	New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs, 2021, 35, 215-227.	2.2	18
90	Safety Implications of the Over-the-Counter Availability of H2-Antagonists. Drug Safety, 1993, 8, 179-185.	1.4	17

#	Article	IF	CITATIONS
91	Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population. European Journal of Clinical Pharmacology, 2001, 57, 343-348.	0.8	17
92	Analysing duration of episodes of pharmacological care: an example of antidepressant use in Danish general practice. Pharmacoepidemiology and Drug Safety, 2006, 15, 167-177.	0.9	17
93	Individualâ€based versus aggregate metaâ€analysis in multiâ€database studies of pregnancy outcomes: the Nordic example of selective serotonin reuptake inhibitors and venlafaxine in pregnancy. Pharmacoepidemiology and Drug Safety, 2016, 25, 1160-1169.	0.9	17
94	Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication. European Journal of Clinical Pharmacology, 2020, 76, 867-876.	0.8	17
95	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple populationâ€based cohort studies. Pharmacoepidemiology and Drug Safety, 2021, 30, 1339-1352.	0.9	17
96	Promotional methods used by representatives of drug companies: A prospective survey in general practice. Scandinavian Journal of Primary Health Care, 2007, 25, 93-97.	0.6	16
97	All Danish first-time COPD hospitalisations 2002–2008: Incidence, outcome, patients, and care. Respiratory Medicine, 2012, 106, 549-556.	1.3	16
98	Hormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins. Menopause, 2015, 22, 369-376.	0.8	16
99	Monotherapy vs. combination therapy for post mania maintenance treatment: A population based cohort study. European Neuropsychopharmacology, 2019, 29, 691-700.	0.3	16
100	Bone bank service in Odense, Denmark. Audit of the first ten years with bone banking at the Department of Orthopaedics, Odense University Hospital. Cell and Tissue Banking, 2001, 2, 179-183.	0.5	15
101	Counting drugs to understand the disease: The case of measuring the diabetes epidemic. Population Health Metrics, 2007, 5, 2.	1.3	15
102	Treatment of 5413 hypertensive patients: a cross-sectional study. Family Practice, 2011, 28, 599-607.	0.8	15
103	Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study. BMC Public Health, 2012, 12, 610.	1.2	15
104	Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations. Journal of Affective Disorders, 2017, 217, 16-23.	2.0	15
105	Artificial Intelligence in Pharmacoepidemiology: A Systematic Review. Part 1—Overview of Knowledge Discovery Techniques in Artificial Intelligence. Frontiers in Pharmacology, 2020, 11, 1028.	1.6	15
106	Impact of socioeconomic status on the use of inhaled corticosteroids in young adult asthmatics. Respiratory Medicine, 2011, 105, 683-690.	1.3	14
107	Family history of cardiovascular disease and influence on statin therapy persistence. European Journal of Clinical Pharmacology, 2014, 70, 701-707.	0.8	14
108	Prevalence of renally inappropriate medicines in older people with renal impairment — A crossâ€sectional registerâ€based study in a large primary care population. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 256-265.	1.2	14

#	Article	IF	CITATIONS
109	Methods for constructing treatment episodes and impact on exposure-outcome associations. European Journal of Clinical Pharmacology, 2020, 76, 267-275.	0.8	14
110	Pharmacoepidemiological methods for computing the duration of pharmacological prescriptions using secondary data sources. European Journal of Clinical Pharmacology, 2021, 77, 1805-1814.	0.8	14
111	Pharmacovigilance Based on Prescription Databases. Basic and Clinical Pharmacology and Toxicology, 2000, 86, 13-15.	0.0	13
112	Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries. Bone, 2020, 134, 115296.	1.4	13
113	Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence. European Journal of Clinical Pharmacology, 2016, 72, 349-357.	0.8	11
114	Cancer patients' first treatment episode with opioids: a pharmaco-epidemiological perspective. Supportive Care in Cancer, 2006, 14, 340-347.	1.0	10
115	The impact of ageing and changing utilization patterns on future cardiovascular drug expenditure: a pharmacoepidemiological projection approach. Pharmacoepidemiology and Drug Safety, 2010, 19, 1276-1286.	0.9	10
116	Predictors for initiation of pharmacological prophylaxis in patients with newly diagnosed bipolar disorder—A nationwide cohort study. Journal of Affective Disorders, 2015, 172, 204-210.	2.0	10
117	Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications. European Journal of Gastroenterology and Hepatology, 2013, 25, 531-538.	0.8	9
118	Initiating therapy with antidepressants after discontinuation of hormone therapy. Menopause, 2013, 20, 146-151.	0.8	9
119	Patients' concern about their medicine after a generic switch: a combined crossâ€sectional questionnaire and register study. Pharmacoepidemiology and Drug Safety, 2014, 23, 965-973.	0.9	9
120	Antipsychotic Prescription Filling in Patients With Schizophrenia or Schizoaffective Disorder. Journal of Clinical Psychopharmacology, 2013, 33, 759-765.	0.7	8
121	Trends in the lifetime risk of COPD exacerbation requiring hospitalisation. European Respiratory Journal, 2013, 42, 964-971.	3.1	8
122	General practitioners choose within a narrow range of drugs when initiating new treatments: a cohort study of cardiovascular drug formularies. European Journal of Clinical Pharmacology, 2005, 61, 651-656.	0.8	7
123	Is a targeted intensive intervention effective for improvements in hypertension control? A randomized controlled trial. Family Practice, 2012, 29, 626-632.	0.8	7
124	The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine. Expert Opinion on Drug Safety, 2020, 19, 349-357.	1.0	7
125	A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. Expert Opinion on Drug Safety, 2021, 20, 467-474.	1.0	7
126	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 61-64.	1.5	6

#	Article	lF	CITATIONS
127	Primary care physicians' adoption of new drugs is not associated with their clinical interests: A pharmacoepidemiologic study. Scandinavian Journal of Primary Health Care, 2011, 29, 117-121.	0.6	6
128	Pharmacological and epidemiological considerations while constructing treatment episodes using observational data: A simulation study. Pharmacoepidemiology and Drug Safety, 2022, 31, 55-60.	0.9	6
129	Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A populationâ€based cohort study in older adults. Clinical and Translational Science, 2022, 15, 2105-2115.	1.5	6
130	Comparison of drug utilization across different geographical areas. , 2016, , 151-159.		5
131	Classification and characteristics of onâ€label and offâ€label apixaban use in Denmark and Sweden. Pharmacoepidemiology and Drug Safety, 2019, 28, 867-878.	0.9	5
132	A Post-Authorization Safety Study of Quetiapine as Antidepressant Treatment in Sweden: Nested Case–Control Analyses of Select Outcomes. Drug Safety, 2020, 43, 135-145.	1.4	5
133	Surveillance of Antidepressant Safety (SADS): Active Signal Detection of Serious Medical Events Following SSRI and SNRI Initiation Using Big Healthcare Data. Drug Safety, 2021, 44, 1215-1230.	1.4	5
134	Artificial Intelligence in Pharmacoepidemiology: A Systematic Review. Part 2–Comparison of the Performance of Artificial Intelligence and Traditional Pharmacoepidemiological Techniques. Frontiers in Pharmacology, 2020, 11, 568659.	1.6	5
135	Fatal adverse drug reactions reported in Denmark 1968–1988. International Journal of Risk and Safety in Medicine, 1991, 2, 305-319.	0.3	4
136	Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction. European Journal of Clinical Pharmacology, 2006, 62, 43-49.	0.8	4
137	Factor analysis improves the selection of prescribing indicators. European Journal of Clinical Pharmacology, 2006, 62, 953-958.	0.8	4
138	On the crest of a wave: Danish prevalence of hospitalisation-required COPD 2002–2009. Respiratory Medicine, 2012, 106, 1396-1403.	1.3	4
139	Adjusting for unmeasured confounding using validation data: Simplified twoâ€stage calibration for survival and dichotomous outcomes. Statistics in Medicine, 2019, 38, 2719-2734.	0.8	4
140	Drug–disease interactions in Swedish senior primary care patients were dominated by non-steroid anti-inflammatory drugs and hypertension – a population-based registry study. Scandinavian Journal of Primary Health Care, 2020, 38, 330-339.	0.6	4
141	The PHARMACOMâ€EPI Framework for Integrating Pharmacometric Modelling Into Pharmacoepidemiological Research Using Realâ€World Data: Application to Assess Death Associated With Valproate. Clinical Pharmacology and Therapeutics, 2022, 111, 840-856.	2.3	4
142	Artificial Neural Network vs. Pharmacometric Model for Population Prediction of Plasma Concentration in Realâ€World Data: A Case Study on Valproic Acid. Clinical Pharmacology and Therapeutics, 2022, 111, 1278-1285.	2.3	4
143	Spontaneous reports of drug-induced erythema multiforme, Stevens - Johnson syndrome and toxic epidermal necrolysis in Denmark 1968-1991. Pharmacoepidemiology and Drug Safety, 1996, 5, 79-86.	0.9	3
144	Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study. Scientific Reports, 2019, 9, 11465.	1.6	3

#	Article	IF	CITATIONS
145	Predictors of quetiapine extendedâ€release formulation addâ€on in older patients exposed to antidepressant drugs: A Danish registerâ€based cohort study. International Journal of Geriatric Psychiatry, 2020, 35, 1156-1162.	1.3	3
146	Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban—A European comparative drug utilization study. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 440-454.	1.2	3
147	Detecting deviations from the efficacy and safety results of singleâ€arm trials using realâ€world data: The case of a CARâ€ī cell therapy in Bâ€cell lymphoma. Pharmacoepidemiology and Drug Safety, 2021, 30, 514-519.	0.9	3
148	Sunshine, temperature and suicidal behaviour in patients treated with antidepressants: an explorative nested case–control study. Scientific Reports, 2021, 11, 10178.	1.6	3
149	Rationale and performances of a data-driven method for computing the duration of pharmacological prescriptions using secondary data sources. Scientific Reports, 2022, 12, 6245.	1.6	3
150	Reply to â€~Evidence for harm, comment on …' by <scp>K</scp> ripke & <scp>L</scp> anger. British Journal of Clinical Pharmacology, 2014, 78, 188-189.	1.1	2
151	Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases. Pharmaceutical Medicine, 2019, 33, 83-88.	1.0	2
152	Investigation of the potential association between the use of fluoxetine and occurrence of acute pancreatitis: a Danish register-based cohort study. International Journal of Epidemiology, 2022, 51, 1656-1665.	0.9	2
153	Incidence of hospital contacts with acute kidney injury after initiation of second-generation antipsychotics in older adults: a Danish population-based cohort study. European Journal of Clinical Pharmacology, 0, , .	0.8	2
154	Season of treatment initiation with antidepressants and suicidal behavior: A population-based cohort study in Sweden. Journal of Affective Disorders, 2017, 215, 245-255.	2.0	1
155	58Cancer risk in long-term users of Valproate: A population-based case-control study. Apmis, 2008, 116, 440-440.	0.9	1
156	Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel—An observational cohort study in Sweden. Pharmacoepidemiology and Drug Safety, 2022, 31, 235-246.	0.9	1
157	Insufficient use of lipid-lowering drugs and measurement of serum cholesterol among patients with a history of myocardial infarction. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 61-4.	1.5	1
158	Current Controversies in Pharmacoepidemiology. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 235-236.	1.2	0
159	Narrow and wide prescribers among general practitioners. European Journal of Clinical Pharmacology, 2006, 62, 577-583.	0.8	0
160	Statin Use and Age at Death: Evidence of a Flawed Analysis. American Journal of Cardiology, 2007, 99, 1181-1182.	0.7	0